KM-Based Herbal Drug Research Group, Korea Institute of Oriental Medicine, Daejeon 305-811, South Korea.
J Ethnopharmacol. 2013 Aug 26;149(1):133-9. doi: 10.1016/j.jep.2013.06.011. Epub 2013 Jun 15.
Dryopteris crassirhizoma has been traditionally used for the treatment of tapeworm infestation, the common cold and cancer in Korea, China and Japan. Despite various pharmacological properties of Dryopteris crassirhizoma, there is no available information about the safety of Dryopteris crassirhizoma.
To ensure more information about the safety of Dryopteris crassirhizoma, we performed the acute oral toxicity and genotoxicity tests of Dryopteris crassirhizoma.
The acute oral toxicity test of Dryopteris crassirhizoma was performed in rats. Genotoxicity of Dryopteris crassirhizoma was evaluated by bacterial reverse mutation, chromosomal aberration and bone marrow micronucleus tests.
In acute toxicity test, Dryopteris crassirhizoma exhibited no mortality, body weight and behavioral changes and adverse effects in male and female rats. Dryopteris crassirhizoma did not significantly increase the number of the bacterial revertant and chromosomal aberration in both in vitro assays. Moreover, the Dryopteris crassirhizoma-related increases of micronucleated polychromatic erythrocytes (MNPCE) in mouse bone marrow were not observed.
Therefore, Dryopteris crassirhizoma is non-genotoxic in a three standard battery of tests and the oral LD50 of Dryopteris crassirhizoma is >2000 mg/kg.
贯众在韩国、中国和日本传统上被用于治疗绦虫感染、普通感冒和癌症。尽管贯众具有多种药理学特性,但目前尚无关于贯众安全性的信息。
为了提供更多关于贯众安全性的信息,我们对贯众进行了急性口服毒性和遗传毒性试验。
在大鼠中进行贯众的急性口服毒性试验。通过细菌回复突变、染色体畸变和骨髓微核试验评估贯众的遗传毒性。
在急性毒性试验中,贯众在雄性和雌性大鼠中未表现出死亡率、体重和行为变化以及不良反应。贯众在体外试验中均未显著增加细菌回复突变体和染色体畸变的数量。此外,在小鼠骨髓中也未观察到与贯众相关的多染红细胞微核(MNPCE)增加。
因此,贯众在三项标准组合测试中无遗传毒性,贯众的口服 LD50 大于 2000mg/kg。